Following the successful completion of a feasibility study, LCB gets exclusive rights globally to exercise its option to develop & commercialize the selected Abs as ADC. If LCB exercises these rights, Glycotope to receive an up front, development & sales milestones along with royalties
The collaboration will combine LCB’s ADC technology platform with Glycotope’s tumor-targeting Abs to develop ADCs for cancer patients. The collaboration further highlights the significance of Glycotope’s distinct technological platform & strengthens Glycotope’s position in the creation of highly selective glyco-epitope targeting Abs
The companies are planning to advance the program to the clinical stage as a competitive cancer therapy
Ref: Globenewswire| Image: LegoChem
